NASDAQ:SBOT Stellar Biotechnologies (SBOT) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free SBOT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.33▼$3.2450-Day Range$4.44▼$298,098.0052-Week Range$0.75▼$3.25Volume1.49 million shsAverage Volume2.95 million shsMarket Capitalization$16.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Stellar Biotechnologies alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Stellar Biotechnologies Stock (NASDAQ:SBOT)Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… SBOT Stock News HeadlinesApril 18, 2024 | techcrunch.comUber, Nvidia-backed Serve Robotics hits public markets with $40M splashJuly 30, 2023 | nypost.comZach Wilson’s stellar day at Jets camp includes long touchdown throwApril 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.June 7, 2023 | forbes.comCaterpillar's Stellar Move To Attract High-Quality EmployeesFebruary 26, 2023 | benzinga.comStellar Bancorp, Inc. Declares Quarterly DividendOctober 5, 2022 | cbsnews.comO's closer Felix Bautista goes on DL ending stellar rookie yearSee More Headlines Receive SBOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stellar Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2019Today4/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SBOT CUSIPN/A CIK1540159 Webwww.stellarbiotechnologies.com Phone805-488-2800FaxN/AEmployees25Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,030,000.00 Net Margins-1,782.64% Pretax MarginN/A Return on Equity-51.12% Return on Assets-48.37% Debt Debt-to-Equity RatioN/A Current Ratio9.24 Quick Ratio8.96 Sales & Book Value Annual Sales$210,000.00 Price / Sales79.70 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book1.48Miscellaneous Outstanding Shares5,330,000Free FloatN/AMarket Cap$16.74 million OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Frank R. Oakes (Age 69)Chairman, Pres & CEO Ms. Kathi Niffenegger CPA (Age 62)CFO & Corp. Sec. Mr. Gary KoppenjanSr. Director of Investor Relations & CommunicationsBrando LincicumExec. Director of Aquaculture and Facility OperationsKey CompetitorsIterum TherapeuticsNASDAQ:ITRMOncternal TherapeuticsNASDAQ:ONCTLisata TherapeuticsNASDAQ:LSTAIndaptus TherapeuticsNASDAQ:INDPAddex TherapeuticsNASDAQ:ADXNView All Competitors SBOT Stock Analysis - Frequently Asked Questions How were Stellar Biotechnologies' earnings last quarter? Stellar Biotechnologies Inc (NASDAQ:SBOT) released its earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.05. The biotechnology company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.11 million. Stellar Biotechnologies had a negative net margin of 1,782.64% and a negative trailing twelve-month return on equity of 51.12%. When did Stellar Biotechnologies' stock split? Stellar Biotechnologies's stock reverse split on the morning of Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 4th 2018. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Stellar Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stellar Biotechnologies investors own include Heat Biologics (HTBX), XOMA (XOMA), Anavex Life Sciences (AVXL), EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Statoil ASA (STO), Abraxas Petroleum (AXAS) and Carrizo Oil & Gas (CRZO). This page (NASDAQ:SBOT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
